Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Pipeline Review, H2 2018
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Pipeline Review, H2 2018
SUMMARY
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Fibroblast growth factor receptor 4 is a protein encoded by the FGFR4 gene. It plays a role in the regulation of cell proliferation, differentiation and migration, and in regulation of lipid metabolism, bile acid biosynthesis, glucose uptake, vitamin D metabolism and phosphate homeostasis. It is required for normal down-regulation of the expression of CYP7A1, the rate-limiting enzyme in bile acid synthesis, in response to FGF19. It phosphorylates PLCG1 and FRS2. Ligand binding leads to the activation of several signaling cascades.
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) pipeline Target constitutes close to 24 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 4, 4, 6, 5 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Metabolic Disorders, Gastrointestinal, Central Nervous System and Musculoskeletal Disorders which include indications Hepatocellular Carcinoma, Solid Tumor, Bile Duct Cancer (Cholangiocarcinoma), Breast Cancer, Gastric Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Lung Adenocarcinoma, Type 2 Diabetes, Esophageal Cancer, Melanoma, Nasopharyngeal Cancer, Non-Alcoholic Steatohepatitis (NASH), Non-Small Cell Lung Cancer, Obesity, Ovarian Cancer, Squamous Non-Small Cell Lung Cancer, Transitional Cell Cancer (Urothelial Cell Cancer), Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Achondroplasia, Adenoid Cystic Carcinoma (ACC), Adrenocortical Carcinoma (Adrenal Cortex Cancer), Anaplastic Thyroid Cancer, Bladder Cancer, Constipation, Endometrial Cancer, Epithelial Ovarian Cancer, Ewing Sarcoma, Fallopian Tube Cancer, Glioblastoma Multiforme (GBM), Head And Neck Cancer, High-Grade Glioma, Liver Cancer, Lymphoma, Metastatic Bile Duct Cancer, Metastatic Biliary Tract Cancer, Metastatic Renal Cell Carcinoma, Metastatic Transitional (Urothelial) Tract Cancer, Osteosarcoma, Peritoneal Cancer, Primary Biliary Cirrhosis, Primary Sclerosing Cholangitis, Primitive Neuroectodermal Tumor (PNET), Prostate Cancer, Recurrent Glioblastoma Multiforme (GBM), Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Renal Cell Carcinoma, Rhabdomyosarcoma, Small-Cell Lung Cancer, Spinal Cord Injury, Squamous Cell Carcinoma, Thymic Carcinoma and Thyroid Cancer.
The latest report Fibroblast Growth Factor Receptor 4 - Pipeline Review, H2 2018, outlays comprehensive information on the Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Fibroblast growth factor receptor 4 is a protein encoded by the FGFR4 gene. It plays a role in the regulation of cell proliferation, differentiation and migration, and in regulation of lipid metabolism, bile acid biosynthesis, glucose uptake, vitamin D metabolism and phosphate homeostasis. It is required for normal down-regulation of the expression of CYP7A1, the rate-limiting enzyme in bile acid synthesis, in response to FGF19. It phosphorylates PLCG1 and FRS2. Ligand binding leads to the activation of several signaling cascades.
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) pipeline Target constitutes close to 24 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 4, 4, 6, 5 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Metabolic Disorders, Gastrointestinal, Central Nervous System and Musculoskeletal Disorders which include indications Hepatocellular Carcinoma, Solid Tumor, Bile Duct Cancer (Cholangiocarcinoma), Breast Cancer, Gastric Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Lung Adenocarcinoma, Type 2 Diabetes, Esophageal Cancer, Melanoma, Nasopharyngeal Cancer, Non-Alcoholic Steatohepatitis (NASH), Non-Small Cell Lung Cancer, Obesity, Ovarian Cancer, Squamous Non-Small Cell Lung Cancer, Transitional Cell Cancer (Urothelial Cell Cancer), Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Achondroplasia, Adenoid Cystic Carcinoma (ACC), Adrenocortical Carcinoma (Adrenal Cortex Cancer), Anaplastic Thyroid Cancer, Bladder Cancer, Constipation, Endometrial Cancer, Epithelial Ovarian Cancer, Ewing Sarcoma, Fallopian Tube Cancer, Glioblastoma Multiforme (GBM), Head And Neck Cancer, High-Grade Glioma, Liver Cancer, Lymphoma, Metastatic Bile Duct Cancer, Metastatic Biliary Tract Cancer, Metastatic Renal Cell Carcinoma, Metastatic Transitional (Urothelial) Tract Cancer, Osteosarcoma, Peritoneal Cancer, Primary Biliary Cirrhosis, Primary Sclerosing Cholangitis, Primitive Neuroectodermal Tumor (PNET), Prostate Cancer, Recurrent Glioblastoma Multiforme (GBM), Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Renal Cell Carcinoma, Rhabdomyosarcoma, Small-Cell Lung Cancer, Spinal Cord Injury, Squamous Cell Carcinoma, Thymic Carcinoma and Thyroid Cancer.
The latest report Fibroblast Growth Factor Receptor 4 - Pipeline Review, H2 2018, outlays comprehensive information on the Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1)
- The report reviews Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Overview
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Companies Involved in Therapeutics Development
Abbisko Therapeutics Co Ltd
Akero Therapeutics Inc
ArQule Inc
Bayer AG
Blueprint Medicines Corp
Eddingpharm Inc
Eisai Co Ltd
Eli Lilly and Co
Everest Medicines Ltd
Genosco Inc
H3 Biomedicine Inc
Hanmi Pharmaceuticals Co Ltd
Incyte Corp
InnoCare Pharma Ltd
Johnson & Johnson
NGM Biopharmaceuticals Inc
Principia Biopharma Inc
Vichem Chemie Research Ltd
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Drug Profiles
ABSK-011 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AKR-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLU-554 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLU-9931 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
derazantinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EDP-317 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
erdafitinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ES-135 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FGF-401 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Proteins to Agonize FGFR for Metabolic Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
golvatinib tartrate + lenvatinib mesylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
H-3B6527 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HM-81442 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ICP-105 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INCB-62079 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
infigratinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lenvatinib mesylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-2874455 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NGM-282 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRN-1371 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rogaratinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit FGFR4 for Solid Tumors - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize FGFR4 for Hepatocellular Carcinoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Pan FGFR for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Dormant Products
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Discontinued Products
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Product Development Milestones
Featured News & Press Releases
Oct 25, 2018: Eisai to present latest data on Lenvima (lenvatinib) and Keytruda (pembrolizumab) combination and exploratory research on a structurally novel class of sting agonist at 33rd SITC annual meeting
Oct 24, 2018: Eisai to present latest data on LENVIMA (lenvatinib) and KEYTRUDA (pembrolizumab) combination at SITC's 33rd Annual Meeting
Oct 19, 2018: QED Therapeutics presents data for Infigratinib in Cholangiocarcinoma in late breaking abstract at the European Society of Medical Oncology 2018 Congress
Oct 10, 2018: Janssen to present on Erdafitinib at ESMO 2018
Oct 10, 2018: Eisai to present Lenvatinib at ESMO 2018 congress
Oct 09, 2018: Bayer to showcase latest oncology research on rogaratinib at ESMO 2018 Congress
Sep 18, 2018: Janssen submits New Drug Application to U.S. FDA seeking approval of Erdafitinib for the treatment of Metastatic Urothelial Cancer
Sep 11, 2018: NICE issues evidence-based recommendations on Lenvatinib for treatment of differentiated thyroid cancer
Sep 11, 2018: Andrew Cheng, MD, PhD joins Akero Therapeutics as President and Chief Executive Officer
Sep 05, 2018: Eisai and Merck announce China National Medical Products Administration (nmpa) approval of lenvima (lenvatinib) for treatment of unresectable hepatocellular carcinoma (hcc)
Aug 29, 2018: Lenvima (lenvatinib) capsules approved for first-line treatment of unresectable hepatocellular carcinoma (HCC) in South Korea
Aug 23, 2018: European Commission grants marketing authorization for LENVIMA (lenvatinib) as first-line treatment in adults with advanced or unresectable hepatocellular carcinoma
Aug 16, 2018: Eisai And Merck Announce FDA Approval Of LENVIMA (lenvatinib) Capsules For First-line Treatment Of Unresectable Hepatocellular Carcinoma (HCC)
Jul 31, 2018: Eisai and Merck, Kenilworth USA announce U.S. FDA grants breakthrough therapy designation for LENVIMA in combination with KEYTRUDA
Jun 29, 2018: CHMP recommends extension of indications for Lenvima
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Overview
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Companies Involved in Therapeutics Development
Abbisko Therapeutics Co Ltd
Akero Therapeutics Inc
ArQule Inc
Bayer AG
Blueprint Medicines Corp
Eddingpharm Inc
Eisai Co Ltd
Eli Lilly and Co
Everest Medicines Ltd
Genosco Inc
H3 Biomedicine Inc
Hanmi Pharmaceuticals Co Ltd
Incyte Corp
InnoCare Pharma Ltd
Johnson & Johnson
NGM Biopharmaceuticals Inc
Principia Biopharma Inc
Vichem Chemie Research Ltd
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Drug Profiles
ABSK-011 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AKR-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLU-554 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLU-9931 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
derazantinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EDP-317 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
erdafitinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ES-135 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FGF-401 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Proteins to Agonize FGFR for Metabolic Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
golvatinib tartrate + lenvatinib mesylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
H-3B6527 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HM-81442 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ICP-105 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INCB-62079 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
infigratinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lenvatinib mesylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-2874455 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NGM-282 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRN-1371 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rogaratinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit FGFR4 for Solid Tumors - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize FGFR4 for Hepatocellular Carcinoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Pan FGFR for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Dormant Products
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Discontinued Products
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Product Development Milestones
Featured News & Press Releases
Oct 25, 2018: Eisai to present latest data on Lenvima (lenvatinib) and Keytruda (pembrolizumab) combination and exploratory research on a structurally novel class of sting agonist at 33rd SITC annual meeting
Oct 24, 2018: Eisai to present latest data on LENVIMA (lenvatinib) and KEYTRUDA (pembrolizumab) combination at SITC's 33rd Annual Meeting
Oct 19, 2018: QED Therapeutics presents data for Infigratinib in Cholangiocarcinoma in late breaking abstract at the European Society of Medical Oncology 2018 Congress
Oct 10, 2018: Janssen to present on Erdafitinib at ESMO 2018
Oct 10, 2018: Eisai to present Lenvatinib at ESMO 2018 congress
Oct 09, 2018: Bayer to showcase latest oncology research on rogaratinib at ESMO 2018 Congress
Sep 18, 2018: Janssen submits New Drug Application to U.S. FDA seeking approval of Erdafitinib for the treatment of Metastatic Urothelial Cancer
Sep 11, 2018: NICE issues evidence-based recommendations on Lenvatinib for treatment of differentiated thyroid cancer
Sep 11, 2018: Andrew Cheng, MD, PhD joins Akero Therapeutics as President and Chief Executive Officer
Sep 05, 2018: Eisai and Merck announce China National Medical Products Administration (nmpa) approval of lenvima (lenvatinib) for treatment of unresectable hepatocellular carcinoma (hcc)
Aug 29, 2018: Lenvima (lenvatinib) capsules approved for first-line treatment of unresectable hepatocellular carcinoma (HCC) in South Korea
Aug 23, 2018: European Commission grants marketing authorization for LENVIMA (lenvatinib) as first-line treatment in adults with advanced or unresectable hepatocellular carcinoma
Aug 16, 2018: Eisai And Merck Announce FDA Approval Of LENVIMA (lenvatinib) Capsules For First-line Treatment Of Unresectable Hepatocellular Carcinoma (HCC)
Jul 31, 2018: Eisai and Merck, Kenilworth USA announce U.S. FDA grants breakthrough therapy designation for LENVIMA in combination with KEYTRUDA
Jun 29, 2018: CHMP recommends extension of indications for Lenvima
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.2), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Products under Development by Companies, H2 2018 (Contd.2), H2 2018
Products under Development by Companies, H2 2018 (Contd.3), H2 2018
Products under Development by Companies, H2 2018 (Contd.4), H2 2018
Products under Development by Companies, H2 2018 (Contd.5), H2 2018
Products under Development by Companies, H2 2018 (Contd.6), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Abbisko Therapeutics Co Ltd, H2 2018
Pipeline by Akero Therapeutics Inc, H2 2018
Pipeline by ArQule Inc, H2 2018
Pipeline by Bayer AG, H2 2018
Pipeline by Blueprint Medicines Corp, H2 2018
Pipeline by Eddingpharm Inc, H2 2018
Pipeline by Eisai Co Ltd, H2 2018
Pipeline by Eli Lilly and Co, H2 2018
Pipeline by Everest Medicines Ltd, H2 2018
Pipeline by Genosco Inc, H2 2018
Pipeline by H3 Biomedicine Inc, H2 2018
Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2018
Pipeline by Incyte Corp, H2 2018
Pipeline by InnoCare Pharma Ltd, H2 2018
Pipeline by Johnson & Johnson, H2 2018
Pipeline by NGM Biopharmaceuticals Inc, H2 2018
Pipeline by Principia Biopharma Inc, H2 2018
Pipeline by Vichem Chemie Research Ltd, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Discontinued Products, H2 2018
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.2), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Products under Development by Companies, H2 2018 (Contd.2), H2 2018
Products under Development by Companies, H2 2018 (Contd.3), H2 2018
Products under Development by Companies, H2 2018 (Contd.4), H2 2018
Products under Development by Companies, H2 2018 (Contd.5), H2 2018
Products under Development by Companies, H2 2018 (Contd.6), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Abbisko Therapeutics Co Ltd, H2 2018
Pipeline by Akero Therapeutics Inc, H2 2018
Pipeline by ArQule Inc, H2 2018
Pipeline by Bayer AG, H2 2018
Pipeline by Blueprint Medicines Corp, H2 2018
Pipeline by Eddingpharm Inc, H2 2018
Pipeline by Eisai Co Ltd, H2 2018
Pipeline by Eli Lilly and Co, H2 2018
Pipeline by Everest Medicines Ltd, H2 2018
Pipeline by Genosco Inc, H2 2018
Pipeline by H3 Biomedicine Inc, H2 2018
Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2018
Pipeline by Incyte Corp, H2 2018
Pipeline by InnoCare Pharma Ltd, H2 2018
Pipeline by Johnson & Johnson, H2 2018
Pipeline by NGM Biopharmaceuticals Inc, H2 2018
Pipeline by Principia Biopharma Inc, H2 2018
Pipeline by Vichem Chemie Research Ltd, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Discontinued Products, H2 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
Abbisko Therapeutics Co Ltd
Akero Therapeutics Inc
ArQule Inc
Bayer AG
Blueprint Medicines Corp
Eddingpharm Inc
Eisai Co Ltd
Eli Lilly and Co
Everest Medicines Ltd
Genosco Inc
H3 Biomedicine Inc
Hanmi Pharmaceuticals Co Ltd
Incyte Corp
InnoCare Pharma Ltd
Johnson & Johnson
NGM Biopharmaceuticals Inc
Principia Biopharma Inc
Vichem Chemie Research Ltd
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
Abbisko Therapeutics Co Ltd
Akero Therapeutics Inc
ArQule Inc
Bayer AG
Blueprint Medicines Corp
Eddingpharm Inc
Eisai Co Ltd
Eli Lilly and Co
Everest Medicines Ltd
Genosco Inc
H3 Biomedicine Inc
Hanmi Pharmaceuticals Co Ltd
Incyte Corp
InnoCare Pharma Ltd
Johnson & Johnson
NGM Biopharmaceuticals Inc
Principia Biopharma Inc
Vichem Chemie Research Ltd
